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Abstract
Background : Markers of pancreatic cancer invasion were investigated in two clonal populations
of the cell line, MiaPaCa-2, Clone #3 (high invasion) and Clone #8 (low invasion) using proteomic
profiling of an in vitro model of pancreatic cancer.
Materials and methods : Using 2D-DIGE followed by MALDI-TOF MS, two clonal sub-
populations of the pancreatic cancer cell line, MiaPaCa-2 with high and low invasive capacities were
incubated on matrigel 24 hours prior to analysis to stimulate cell-ECM contact and mimic in vivo
interaction with the basement membrane.
Results : Sixty proteins were identified as being differentially expressed (> 1.2 fold change and p
≤ 0.05) between Clone #3 and Clone #8. Proteins found to have higher abundance levels in the
highly invasive Clone #3 compared to the low invasive Clone #8 include members of the chaperone
activity proteins and cytoskeleton constituents whereas metabolism-associated and catalytic
proteins had lower abundance levels. Differential protein expression levels of ALDH1A1, VIM,
STIP1 and KRT18 and GAPDH were confirmed by immunoblot. Using RNAi technology, STIP1
knockdown significantly reduced invasion and proliferation of the highly invasive Clone #3.
Knockdown of another target, VIM by siRNA in Clone #3 cells also resulted in decreased invasion
abilities of Clone #3. Elevated expression of STIP1 was observed in pancreatic tumour tissue
compared to normal pancreas, whereas ALDH1A1 stained at lower levels in pancreatic tumours,
as detected by immunohistochemistry.
Conclusion : Identification of targets which play a role in the highly invasive phenotype of
pancreatic cancer may help to understand the biological behaviour, the rapid progression of this
cancer and may be of importance in the development of new therapeutic strategies for pancreatic
cancer.
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Background
Pancreatic cancer is the tenth most common cancer in
Europe, and accounts for approximately 2.5% of cancer in
males and females [1]. The median survival is 8–12
months for patients presenting with locally advanced and
unresectable disease, and only 3–6 months for those with
metastatic disease at presentation [2]. Surgery offers the
best curative treatment, but < 15% of patients present
with tumours eligible for resection at initial diagnosis due
to aggressive local and perineural invasion, early metasta-
sis to liver and lymph nodes, formation of desmoplastic
stromal reaction within the tumour and resistance to
chemotherapy and radiation [3]. Therefore, there is an
urgent need to develop molecular diagnostic biomarkers
and targets to detect pancreatic cancer at an earlier stage,
which may help to improve treatment and survival of pan-
creatic cancer patients. The development of invasive and
metastatic pancreatic cancer is complex and poorly under-
stood. Metastasis is defined as the ability of tumour cells
at the primary site to invade local tissue, cross the base-
ment membrane and tissue barriers and re-establish at
distant secondary locations. This process of metastasis is
not random. A cascade of complex interactions between
the cancer cell and its surroundings results in the meta-
static cascade; Tumour cells must first break signalling
contact with neighbouring cells, degrade and penetrate
the basement membrane and then invade the interstitial
stroma in order to reach blood/lymph vessels [4]. Intrava-
sation requires penetration of the blood/lymph systems.
The tumour cells must then exit the lymph system or
blood stream at a new site (extravasation) and proliferate
in the secondary organ [5]. The heterogeneous nature of
some tumours is associated with sub-populations of
highly metastatic tumour cells existing at very early stages
of primary tumour development [6]. We previously iso-
lated clonal sub-populations of the human pancreatic
cancer cell line, MiaPaCa-2 through serial dilution. Two of
these sub-clones, Clone #3 and Clone #8, displayed
altered malignant properties. Clone #3 showed higher
invasion with low levels of adhesion, while Clone #8 dis-
played decreased invasion with increased adhesion to
ECM proteins. Clone #8 was sensitive to anoikis, and dis-
played low colony-forming efficiency in an anchorage-
independent growth assay compared to Clone #3. This
model provides a unique in vitro representation of an
invasive pancreatic carcinoma. The aim of this study was
to identify novel proteins involved in pancreatic cancer
invasion using an in vitro model of pancreatic cancer inva-
sion. Protein expression of Clone #3 (highly invasive) and
Clone #8 (low level of invasion) were compared using
2D-DIGE followed by MALDI-TOF-MS for protein profil-
ing.
Results
Invasion assays
Two clonal populations, Clone #3 and Clone #8 were iso-
lated from the human pancreatic cancer cell line, Mia-
PaCa-2. Clone #3 is highly invasive compared to the
parent MiaPaCa-2, whilst Clone #8 displays distinctively
less invasion than the parent as shown by the total
number of cells invading after preincubation on matrigel
for 24 hrs (Fig 1).
Identification of proteins by 2D-DIGE analysis
To investigate proteins potentially involved in invasion in
this model for human pancreatic cancer, we systematically
analysed protein expression from Clone #3 and Clone #8
grown on matrigel 24 hours prior to protein extraction
using 2D-DIGE. Biological variation analysis of spots
showing greater than 1.2-fold change in expression with a
t-test score of less than 0.05, revealed 60 differentially
expressed proteins between Clone #3 and Clone #8 (Fig 2
and Table S1 Additional file 1). Table S1 is a list of the dif-
ferentially expressed proteins with their protein accession
numbers, % coverage, theoretical pI, and molecular
weight, calculated fold change, P  values and function-
(Human Protein Reference Database (HPRD)) http://
www.hprd.org. Theoretical pI and MW provides informa-
tion not only on full-length protein expression, but
expression of modified, splice variant, cleavage product,
and processed proteins. Any protein modification that
leads to a change in overall protein charge and/or molec-
ular weight (MW) will generate a different spot on the 2D
gel. Modification specific staining can identify whether a
specific post-translational modification is responsible for
the shift, and mass spectrometry can potentially identify
the source of isoelectric point (pI) and/or MW differences.
Of the 60 proteins identified, 49 of these proteins were
found in higher abundance and 11 were expressed at
lower levels in the highly invasive Clone #3. Many highly
expressed proteins in Clone #3 correspond to the
cytoskeleton (vimentin, vinculin, tubulin alpha-6, beta-
tubulin, alpha-tubulin and gamma-actin), the chaperone
family of proteins (heat shock proteins, KIAA0098, stress-
induced phosphoprotein 1 and MTHSP75). Other highly
abundant proteins included some associated with transla-
tion and transport, receptor signalling and ligase activity.
Among the 11 low abundant proteins, most are involved
in the catalytic/glycolysis activity. Keratin 18 (KRT18), a
cytoskeletal protein is 2.9-fold less abundant in Clone #3
cells, and low expression of KRT18 has been previously
implicated in a more aggressive phenotype [7].
Gene ontology enrichment analysis
Using DAVID gene ID tool software http://
david.abcc.ncifcrf.gov, all the proteins differentially
expressed in our model were converted to their gene IDs.Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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Gene ontology (GO STAT) http://gostat.wehi.edu.au/cgi-
bin/goStat.pl was then used to classify the proteins and
their corresponding genes into gene categories and assign
functional categories. Enrichment of a particular ontology
term, for significantly expressed genes in response to the
process under study, means that the ontology term is
likely to be involved in the process. In our study, the proc-
ess refers to invasion in pancreatic cancer. Using the over-
expression function of the software and false discovery
rate (Benjamini) stats, 52 GO terms were found signifi-
cantly enriched between Clone #3 versus Clone #8. The
molecular functions of the proteins identified in this
study were classified according to GO database. Figure 3
displays the top 10 GO biological process categories of
invasion-related differentially expressed proteins in our
pancreatic cancer model. Profiles based on differentially
expressed proteins showed clear differences between the
two cell lines. For example, the "cytoplasm" term
achieved the highest degree of significance in the up-regu-
lated gene class (p  = 1.40E-09), with "glycolysis" (p  =
4.05E-07) and "nucleotide binding" (p = 1.04E-06) also
highly significant terms. In the down-regulated class, "oxi-
doreductase activity" (p = 0.0006), "aldehyde dehydroge-
nase activity" (p = 0.003) and "mitochondrion" (p = 0.03)
were also significantly enhanced.
Confirmation of identified proteins by immunoblot 
analysis
Immunoblot analysis was carried out to confirm the dif-
ferential expression observed for A. ALDH1A1, B. VIM, C.
STIP1, D. KRT18 and E. GAPDH in Clone #3 and Clone
#8. In all cases, the results were consistent with proteomic
analysis. Figure 4 (A-E) details the high and low abun-
dance of proteins by (i) 3D spot image, (ii) protein expres-
sion map and (iii) immunoblot in the comparison of
Clone #3 versus Clone #8.
A novel role for stress-induced phosphoprotein 1 (STIP1) in 
invasion
STIP1 expression levels were 2-fold higher in Clone #3
compared to Clone #8. Invasion assays were carried out
on untreated Clone #3 cells, cells treated with scrambled
siRNA and three independent siRNAs for STIP1 (Fig 5A
and 5B). STIP1 siRNA transfection significantly reduced
the invasion of Clone #3 cells (3-fold (p = 0.0002) with
STIP1-siRNA (1), 2-fold (p = 0.0002) with STIP1-siRNA
(2) and 2-fold (p = 0.0003) with STIP1-siRNA (3). STIP1
had no effect on adhesion (data not shown), however,
transfection of Clone #3 cells with STIP1-siRNAs
decreased proliferation by 13% (p = 0.04) with STIP1-
siRNA (1) and 27% (p = 0.003) with STIP1-siRNA (2).
Graph displays the total number of cells invading after 24 hr incubation on matrigel of Clone #8, MiaPaCa-2 and Clone #3 Figure 1
Graph displays the total number of cells invading after 24 hr incubation on matrigel of Clone #8, MiaPaCa-2 
and Clone #3. Experiments performed in triplicate.Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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STIP1-siRNA (3) did not alter the proliferation of the cells
(Fig 5C).
Vimentin (VIM) involvement in the invasion of pancreatic 
cancer cells
VIM was detected at 5.5-fold higher levels in Clone #3
compared to Clone #8. Transfection of VIM-siRNAs
reduced the expression of VIM in Clone #3 cells (Fig 6A).
Invasion of VIM-siRNA transfected Clone #3 cells reduced
invasion 4-fold (p = 0.00036) with VIM-siRNA (1), 6-fold
(p = 0.00031) with VIM-siRNA (2) and 6-fold (p = 0.0004)
with VIM-siRNA (3) (Fig 6B).
Representative 2D DIGE gel image of Cy2-labelled pool of Clone #3 and Clone #8 cell lysate samples Figure 2
Representative 2D DIGE gel image of Cy2-labelled pool of Clone #3 and Clone #8 cell lysate samples. Differen-
tially expressed proteins that have been successfully identified by MALDI-TOF MS (p ≤ 0.05, protein fold ≥ 1.2) are repre-
sented on the gel using DeCyder software. Proteins are labelled numerically for visual clarity and are outlined in Table S1.Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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Immunohistochemical (IHC) analysis of STIP1 and 
ALDH1A1 in pancreatic tissue
IHC analysis was performed on pancreatic cancer (PC) tis-
sue (n = 5) and corresponding normal pancreas (NP) tis-
sue specimens (n = 5). IHC was used to validate the
expression patterns of two proteins, STIP1 and ALDH1A1.
In all cases STIP1 exhibited strong cytoplasmic staining in
5/5 PC specimens, concentrating strongest in areas of
perineural invasion and necrotic cells in the epithelium
(Fig 7A–C). However, STIP1 expression was also observed
in the normal ductal and acinar cells of the exocrine pan-
creas (Fig 7D). STIP1 also stained surrounding duode-
num, indicating that STIP1 may not be specific to the
pancreas, but may have potential as a target for invasive
cancer. Overall, increased STIP1 expression was observed
in the tumour compared to normal tissues (Fig 7A–D).
Strong ALDH1A1 expression was observed in 2/5 PC (Fig
7E). This may be associated with differentiation status, as
strong ALDH1A1 expression was exclusive to well differ-
entiated tumours (Table 1). Three moderate-poorly differ-
entiated pancreatic cancer samples exhibited lower levels
(< 10%) of ALDH1A1 (Fig 7F–G). ALDH1A1 staining was
also observed in normal pancreas (Fig 7H), including islet
cells.
Discussion
In this study, clonal sub-populations of the human pan-
creatic cancer cell line, MiaPaCa-2 were established and
their invasion status assessed. Pancreatic cancer is charac-
terised by early invasion and metastasis. As the invasive
and metastatic cascade involves the interaction, attach-
ment and degradation of the basement membrane in vivo,
we allowed the cells grow on matrigel for 24 hours prior
to proteomic analysis, to mimic the cells contact with the
Term-ranking Gene Ontology categories Figure 3
Term-ranking Gene Ontology categories. Representation of the 10 top-ranked functional categories, using GO terms 
that are enriched in all significantly differentially expressed proteins between Clone #3 versus Clone #8.Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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Differentially expressed proteins, A. ALDH1A1, B. VIM, C. STIP1, D. KRT18 and E. GAPDH in Clone #3 versus Clone #8 con- firmed by (i) 3D spot image, (ii) PEM spot and (iii) immunoblot Figure 4
Differentially expressed proteins, A. ALDH1A1, B. VIM, C. STIP1, D. KRT18 and E. GAPDH in Clone #3 versus 
Clone #8 confirmed by (i) 3D spot image, (ii) PEM spot and (iii) immunoblot.Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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Figure 5 (see legend on next page)Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
Page 8 of 14
(page number not for citation purposes)
basement membrane. In this study, sixty proteins were
identified as differentially expressed between Clone #3
and Clone #8 by 2D DIGE followed by MALDI-TOF MS.
Bio-informatic profiling of the proteins identified was
performed using GO (gene ontology). The GO STAT pro-
filing of the differentially abundant proteins between
Clone #3 and Clone #8 provided overall analysis of
molecular functional changes in these cells. GO STAT
analysis showed that proteins of higher abundance in this
study are more related to the cytoplasm, ATP and nucle-
otide binding, while some proteins of lower abundance
were exclusively classified as involved in the mitochon-
drion, suggesting loss of special organelle functions.
Three novel proteins, ALDH1A1, STIP1 and VIM were
chosen to validate and further investigate their involve-
ment in pancreatic cancer invasion.
ALDH1A1 was expressed at higher levels in the more inva-
sive, Clone #3. ALDH1A1 is an enzyme involved in the
conversion of aldehydes to their corresponding acids by
NAD (P)+ dependent reactions [8]. ALDH1A1 activity in
cancer has been found to be responsible for resistance to
oxazaphosphorines such as cyclophosphamide [9,10] and
is involved in the irreversible oxidization of retinal to
retinoic acid (RA) [11], which has been associated with
invasion and adhesion in pancreatic cancer cell lines
[12,13]. Expression of ALDH1A1 was shown to be up-reg-
ulated in the highly malignant ovarian cancer cell line,
TOV-112D compared to the low malignant TOV-81D
[14]. ALDH1A1 expression has been linked to more
aggressive tumours suggesting a possible role in the inva-
sive/drug resistance pathways.
Proteins involved in folding, stress response and degrada-
tion were also identified as important in our model.
Molecular chaperones and folding enzymes are responsi-
ble for protein folding. Stress-induced phosphoprotein 1
(STIP1) was + 2.0-fold expressed in the highly invasive
Clone #3 compared to Clone #8 (low invasion). STIP1
(Hsp70/Hsp90-organising protein (Hop)) mediates the
association of the molecular chaperones Hsp70 and
Hsp90 [15]. Heat shock proteins, Hsp90 and Hsp70 have
previously been implicated in pancreatic cancer [16,17].
Eustace et al. [18] showed that Hsp90α chaperone-com-
plex interactions are involved in MMP-2 activity and inva-
siveness in the fibrosarcoma cell line, HT-1080. STIP1
expression, through survival pathways and MMP activa-
tion, could contribute to invasion in the highly invasive
Clone #3 pancreatic cancer cell line, therefore making it a
potentially valuable target for pancreatic cancer therapy.
Recently Sun et al. [19] confirmed the over expression of
STIP1 (HOP) in hepatocellular carcinoma (HCC) by 2D
fluorescence DIGE proteomic analysis. STIP1 is secreted
by and shown to induce proliferation in glioma tumour
cells through MAPK and P13 pathways [20].
VIM is a component of intermediate filaments (IF) of the
cytoskeleton and is important in cell motility and move-
ment, maintaining cell shape, integrity of the cytoplasm
and stabilising cytoskeletal interactions. Proteomic analy-
sis revealed an increased expression of VIM in the highly
invasive Clone #3 compared to the low invasive Clone #8.
Reduction of VIM expression by siRNA decreased the inva-
sion of Clone #3 revealing a role for VIM in pancreatic
cancer cell invasion. Many studies have shown VIM to be
substantially expressed in liver metastases of pancreatic
tumours [21], and expression is associated with increased
invasiveness and metastasis potential for epithelial breast
carcinoma [22], hepatocellular carcinoma [23] and cervi-
cal carcinoma [24]. Co-expression of VIM and cytokerat-
ins (CKs) is associated with a more aggressive and
metastatic phenotype in breast cancer [22,25]; however
our data demonstrates increased expression of VIM with
an associated decrease in cytokeratin 18 levels in Clone
#3. Singh et al. [26] found that VIM expression contrib-
uted to the invasive phenotype of prostate cancer cell lines
but could function at later stages of the invasive process.
The high expression levels of VIM in our invasive cell line
could represent a marker for the epithelial to mesenchy-
mal transition (EMT), in agreement with previous pancre-
atic cancer studies [27,28]. Therefore, expression of VIM
could be a confirmatory marker for EMT to a more aggres-
sive phenotype. Javle et al. [29] found that EMT correlates
with the activation of PI3 kinase and Ras/Erk pathways,
which are known to be involved in invasion. Loss of VIM
A. Immunoblot of STIP1 silencing in Clone #3 cells untreated control, scrambled control, STIP1-siRNA (1), STIP1-siRNA (2)  and STIP1-siRNA (3) (upper) and α-tubulin as loading control (lower) Figure 5 (see previous page)
A. Immunoblot of STIP1 silencing in Clone #3 cells untreated control, scrambled control, STIP1-siRNA (1), 
STIP1-siRNA (2) and STIP1-siRNA (3) (upper) and α-tubulin as loading control (lower). B. Total number of invad-
ing cells after siRNA transfection in Clone #3 untreated control, scrambled control, STIP1-siRNA (1), STIP1-siRNA (2) and 
STIP1-siRNA (3). Results are displayed as the total number of invading cells, determined by counting the number of cells per 
field in 10 random fields, at 200× magnification. The average number of cells per field was then multiplied by a factor of 140 
(growth area of membrane/field area viewed at 200× magnification (calibrated using a microscope graticule)). Experiments per-
formed in triplicate. Total mean number of cells invading at 200× magnification (n = 3). C. Proliferation assays of Clone #3 
untreated control, scrambled control, STIP1-siRNA (1), STIP1-siRNA (2) and STIP1-siRNA (3). Results displayed as percentage 
survival relative to untreated control. Student's t-test; p = 0.05*, 0.01**, 0.005*** (n = 3).Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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A. Immunoblot of VIM knockdown in Clone #3 untreated control, scrambled control, VIM-siRNA (1), VIM-siRNA (2) and VIM- siRNA (3) (upper) and α-tubulin as loading control (lower) Figure 6
A. Immunoblot of VIM knockdown in Clone #3 untreated control, scrambled control, VIM-siRNA (1), VIM-
siRNA (2) and VIM-siRNA (3) (upper) and α-tubulin as loading control (lower). B. Invasion assay of Clone #3 cells 
after siRNA silencing of VIM. The total number of invading cells was determined by counting the number of cells per field in 10 
random fields, at 200× magnification. The average number of cells per field was then multiplied by a factor of 140 (growth area 
of membrane/field area viewed at 200× magnification (calibrated using a microscope graticule)). Experiments performed in trip-
licate. Statistics; * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.005.Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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IHC detection of STIP1 (A-D) and ALDH1A1 (E-H) in pancreatic cancer and normal pancreas tissues Figure 7
IHC detection of STIP1 (A-D) and ALDH1A1 (E-H) in pancreatic cancer and normal pancreas tissues. (A) 
Strong STIP1 cytoplasmic staining in PC tumour ducts. (B-C) Strong STIP1 expression in poorly differentiated PC tumours. 
(D) Moderate staining of normal pancreas ducts and acinar cells. (E) ALDH1A1 highly expressed in well differentiated PC 
tumour. (F-G) Weak ALDH1A1 staining observed in < 10% of poorly differentiated PC tumours. (H) Positive staining in epi-
thelial cells of normal pancreas. Original magnification 200×.Proteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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expression, up-regulation of adhesion proteins and
reduced aggressiveness of in vitro invasion is associated
with KRT18 expression [7]. However, conflicting reports
have implicated KRT18 expression in carcinogenesis met-
astatic hepatocellular carcinoma (HCC) tissue [30] and as
a predictive marker for lymph node metastasis in esopha-
geal squamous cell cancer [31].
Conclusion
In summary, knockdown of STIP1 and VIM by siRNA
resulted in decreased invasion and proliferation (STIP1)
in the highly invasive pancreatic cancer cell line, Clone #3.
Expression of STIP1 and ALDH1A1 in pancreatic tissue
was investigated using IHC analysis of pancreatic tumour
and normal tissue. This is the first time that STIP1 and
ALDH1A1 have been implicated in invasion and investi-
gated in pancreatic tissue. Our results showed increased
expression of STIP1 in ductal and highly invasive adeno-
carcinoma cells in the tumours with weaker positive stain-
ing in normal pancreas ducts and acinar cells. Staining of
ALDH1A1 was mainly concentrated to < 10% of tumour
cells in 3/5 poorly differentiated PC specimens. ALDH1A1
expression was also observed in the stromal and epithelial
cells of the normal pancreas.
The proteomic profiling of pancreatic cancer cell lines
with different invasion status from the same genetic back-
ground could help to elucidate the molecular mecha-
nisms of pancreatic cancer invasion and may represent an
in vitro model for pancreatic metastasis. The proteins iden-
tified in this study as involved in pancreatic cancer cell
invasion may have potential as novel therapeutic targets
and tumour markers of pancreatic cancer. However, the
implication of these unique proteins identified as poten-
tial candidates associated with highly invasive pancreatic
cancer needs to be fully evaluated. A large clinical study
including serum samples, tissue and pancreatic juice,
would be required in order to identify these proteins as
potentially useful for diagnosis, staging, prognosis and
response to therapy of pancreatic cancer.
Methods
Cell lines
The human pancreatic cell line MiaPaCa-2 was obtained
from the European Collection of Cell Cultures (ECACC,
UK). Clone #3 and Clone #8 were obtained by single cell
dilution in this laboratory. Briefly the parental cell line
was diluted to a concentration of 3 cells/ml and 100 μl
plated onto each well of a 96-well plate. After 24 hours
each well was studied for single cells, and allowed to grow
into colonies. The colonies were then screened by inva-
sion assay to assess their invasive abilities. Cells were
maintained in a humidified atmosphere containing 5%
CO2  at 37°C in DMEM supplemented with 5% FCS
(Sigma-Aldrich). Antibiotics were not used in the growth
media. All cell lines were free from Mycoplasma as tested
with the indirect Hoechst staining method.
Preincubation of cells with matrigel coated flasks
Matrigel (Sigma-Aldrich, UK) was coated onto flasks (1
ml/25 cm2) at a concentration of 1 mg/ml. The coated
flasks were then placed at 4°C overnight. The flasks were
placed into an incubator at 37°C for approximately 2 hrs
to allow the matrigel polymerise. The excess media in the
flasks was then removed and fresh complete media con-
taining the cell suspension was added. Cells attached to
the matrigel on the bottom of the flask and after 24 hrs
were removed with 0.5 ml/T25 cm2 dispase (BD Bio-
sciences). Dispase is a bacillus derived neutral metalopro-
tease that recovers cells cultured on matrigel.
Invasion assays
Invasion assays were performed as previously described
[32]. 100 μl of matrigel (1 mg/ml) was placed into each
invasion insert (Falcon) (8.0 μm pore size) in a 24 well
plate (Costar). The coated inserts were incubated over-
night at 4°C. Matrigel was allowed polymerize at 37°C for
1 hr, then washed with serum-free DMEM. 100 μl of fresh
DMEM containing 5% serum was added to the wells and
1 × 105/100 μl cells were seeded onto the insert. 500 μl of
fresh DMEM with 5% serum was added to the well. After
24 hour incubation, the inside of the insert was wiped
with a wet cotton swab. The under surface was gently
rinsed with PBS and stained with 0.25% crystal violet for
10 minutes, rinsed again with sterile water and allowed to
dry. To determine total number of invading cells, the
inserts were then viewed under the microscope and the
number of cells per field in 10 random fields were
counted at 200× magnification. The average number of
cells per field was then multiplied by a factor of 140
Table 1: Type of pancreatic cancer included in the study
Sex Age Tumour Type Tumour Grade Lymph node status
PC-01 M 48 Adenocarcinoma, ductal Moderately differentiated +ve
PC-02 F 43 Adenocarcinoma Well differentiated -ve
PC-03 F 67 Adenocarcinoma Well differentiated -ve
PC-04 M 36 Adenocarcinoma Poorly differentiated +ve
PC-05 M 67 Squamous cell Poorly differentiated No nodesProteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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(growth area of membrane/field area viewed at 200× mag-
nification (calibrated using a microscope graticule)). The
mean values were obtained from a minimum of three
individual experiments and were subjected to t-tests.
Sample preparation and protein labelling
Cells at approximately 80% confluency were washed
twice in PBS, twice in sucrose buffer before lysing in buffer
containing 4% w/v CHAPS, 7 M urea, 2 M thiourea, 10
mM Tris-HCL, 5 mM magnesium acetate pH 8.5, and then
homogenized by passing through a 25-gauge needle six
times. Insoluble material was removed by centrifugation
at 14000 rpm for 20 min at 10°C. Protein concentration
was determined using the BCA protein assay kit (Bio-
Rad). 50 μg of each biological repeat lysate was labelled
with Cy3 and Cy5 (200 pmol) in the dark for 30 min and
quenched with 50-fold molar excess of free lysine-to-dye.
Samples were reverse-labelled in order to enable all com-
parisons and eliminate any dye-labelling bias. Reverse-
labelling allows one to differentiate between sample-
dependent differences and rare dye-dependent differ-
ences.
Samples were mixed and run on the same gels with an
equal amount (50 μg) of Cy2-labeled standard. Cy2 was
used as a standard on all gels to aid image matching and
cross-gel statistical analysis [33].
Protein separation by 2-DE and gel imaging
Immobilised 24 cm linear pH gradient (IPG) strips, pH 3–
11, were rehydrated in rehydration buffer (7 M urea, 2 M
thiourea, 4% CHAPS, 0.5% IPG buffer, 50 mM DTT) over-
night, according to manufactures guidelines. IEF was per-
formed using as IPGphor apparatus (GE Healthcare) for
40 kV/h at 20°C with resistance set at 50 mA. Strips were
equilibrated for 20 min in 50 mM Tris-HCL, pH 8.8, 6 M
urea, 30% v/v glycerol, 1% w/v SDS containing 65 mM
DTT and then for 20 min in the same buffer containing
240 mM iodoacetamide. Equilibrated IPG strips were
transferred onto 18 × 20 cm 12.5% uniform polyacryla-
mide gels poured between low fluorescence glass plates.
Strips were overlaid with 0.5% w/v low melting point aga-
rose in running buffer containing bromophenol blue.
Gels were run at 2.5 W/gel for 30 min and then 100 W
total at 10°C. All the images were collected on a Typhoon
9400 Variable Mode Imager (GE Healthcare). Statistics
and quantification of protein expression were carried out
in DeCyder software (GE Healthcare).
Spot digestion and MALDI-TOF analysis
Excision of protein spots, trypsin digestion and protein
identification by MS analysis using an Ettan MALDI-TOF
Pro (GE Healthcare) was performed. Preparative gels con-
taining 300 μg of protein were fixed in 30% v/v methanol,
7.5% v/v acetic acid overnight and washed in water, and
total protein was detected by post-staining with CBB and
Deep purple stain (Molecular Probes) for 3 hrs at room
temperature. Excess dye was removed by washing twice in
water, and gels were imaged using a Typhoon 9400 Varia-
ble Mode Imager (GE Healthcare) at the appropriate exci-
tation and emission wavelengths for the stain. The
subsequent gel image was imported into the BVA module
of DeCyder software and was matched to images gener-
ated from DIGE analysis. Spots of interest were selected
and confirmed using this software for subsequent picking
using an Ettan Spot Picker. Gel plugs were placed into a
presiliconised 1.5 ml plastic tube for destaining, desalting
and washing steps. The remaining liquid above the gel
plugs was removed and sufficient ACN was added in order
to cover the gel plugs. Following shrinkage of the gel
plugs, ACN was removed and the protein containing gel
pieces were rehydrated for 5 min with a minimal volume
of 100 mM ammonium bicarbonate. An equal volume of
ACN was added, and after 15 min of incubation the solu-
tion was removed from the gel plugs and the samples were
dried for 30 min using a vacuum centrifuge. Individual gel
pieces were then rehydrated in digestion buffer (12.5 ng
trypsin per μl of 10% ACN, 40 mM ammonium bicarbo-
nate) to cover the gel pieces. Exhaustive digestion was car-
ried out overnight at 37°C. After digestion, the samples
were centrifuged at 12000 × g for 10 min using a bench
top centrifuge. The supernatant was carefully removed
from each sample and placed into clean plastic tubes.
Samples were stored at -80°C until analysed by M.S. For
spectrometric analysis, mixtures of tryptic peptides from
individual samples were desalted using Millipore C-18
Zip-Tips (Millipore) and eluted onto the sample plate
with the matrix solution (5 mg/ml CHCA in 50% ACN/
0.1% TFA v/v). Mass spectra were recorded using the
MALDI-TOF instrument operating in the positive reflec-
tron mode at the following parameters: accelerating volt-
age 20 kV; and pulsed extraction; on (focus mass 2500).
Internal calibration was performed using anti-analysis
peaks at m/z 842.50, m/z 2211.104 and external calibra-
tion was performed using Pep4 mix. The mass spectra
were analysed using MALDI evaluation software (GE
Healthcare), and protein identification was achieved with
the PMF Pro-Found search engine. An expectation value of
< 0.002 was used for all reported identifications, which
indicates a 0.2% chance the identification is random.
Immunoblotting
Whole protein was extracted from cell lysates using 1×
lysis buffer (50 mM Tris-Cl, 150 mM NaCl, and 0.5% NP-
40). Lysates were centrifuged for 10 min at 14,000 rpm at
4°C. Protein concentrations were determined using the
Bio-Rad protein assay (Bio-Rad). 35 μg of protein was sep-
arated by 7.5% and 15% SDS-PAGE under reducing con-
ditions. Proteins were transferred to nitrocellulose
membrane, efficiency and equal loading of protein wasProteome Science 2009, 7:3 http://www.proteomesci.com/content/7/1/3
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visualised by Ponceau S staining. Membranes were
blocked at 4°C overnight in TBS (25 mM Tris-HCl, pH
7.4, 150 mM NaCl, 2.7 mM KCl) containing 5% (w/v)
low fat milk powder. Membranes were probed with mon-
oclonal antibodies, anti-aldehyde dehydrogenase
(Abcam), anti-stress-induced phosphoprotein 1 (Santa
Cruz) (Abcam), anti-cytokeratin 18 (Santa Cruz Biotech-
nology), anti-vimentin (Sigma), anti-GAPDH (Applied
Biosystems). Secondary antibodies, anti-mouse, anti-rab-
bit and anti-goat were obtained from Sigma. Protein
bands were detected with Luminol reagent (Santa Cruz
Biotechnology).
siRNA transient transfections
Three pre-designed STIP1 and VIM-siRNAs (Ambion)
were chosen and transfected into cells. For each set of
siRNA transfections carried out, a control (non-trans-
fected) and a scrambled (SCR) siRNA transfected control
were used. siRNA experiments were set up using 2 μl
NeoFx to transfect 30 nM siRNA in a cell density of 3 × 105
per well of a 6-well plate. Transfection medium was
removed after 24 hours and replaced with fresh growth
medium. The transfected cells were collected for immuno-
blot and assayed for changes in invasion capacity at 48
hours using the in vitro invasion assay (as previously
described).
IHC Analysis
Patients
The patient group consisted of 5 consenting patients diag-
nosed with primary tumours of the pancreas. All patients
were treated at St. Vincent's University Hospital (SVUH),
Dublin in 2005. IHC studies on tumour-free pancreatic
tissue were performed using corresponding non-cancer-
ous tissue. Pathological material was examined on each
case by SK. Formalin-fixed paraffin-embedded pancreatic
tumour tissue and corresponding normal pancreas was
available for all patients. Representative 4-μm sections of
tissue block were cut using a microtome, mounted onto
poly-l-lysine coated slides and dried overnight at 37°C.
Slides were stored at room temperature until required.
Immunohistochemistry
Briefly the slides were immunohistochemically stained
using primary antibodies specific for ALDH1A1 and STIP1
from Abcam. The staining procedure includes an antigen
retrieval step consisting of 20-minute incubation in pH
9.0 buffer (TARGET Retrieval, Dako) in a 95°C water bath
followed by cooling to room temperature. Staining was
performed using an automated staining apparatus for IHC
(Autostainer, Dako) according to the manufacturer's
guidelines. The slides were counterstained with haema-
toxylin.
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